Clinical Data Foundries Are on the Horizon

Why It Matters

By converting passive patient records into revenue‑generating data assets, providers can offset financial strain while accelerating drug discovery and real‑world evidence generation across the health‑tech ecosystem.

Key Takeaways

• Data‑foundry market projected to reach $293 M by 2030 (15% CAGR).
• Modular AI replaces fragmented point solutions, enabling plug‑and‑play integration.
• MCP acts as “USB‑C” for AI agents, standardizing health data connections.
• De‑identification costs range $2.4k–$21k per million documents, influencing scalability.
• Public trust varies; only 26% comfortable sharing data with commercial tech firms.

Pulse Analysis

The financial squeeze on hospitals and health systems has forced a strategic re‑evaluation of the electronic health record. Rather than a compliance‑only artifact, the clinical record is being recast as a high‑margin data asset that can be licensed to pharmaceutical, med‑tech and technology partners. This re‑positioning aligns with broader macro‑economic trends—labor shortages, rising care costs, and compressed margins—creating a new revenue engine that can fund both operational needs and innovation pipelines.

At the technical core of the emerging data‑foundry model is a modular AI architecture anchored by the Model Context Protocol (MCP). MCP functions like a universal USB‑C connector, allowing AI agents to interface with EHRs, imaging archives, and lab systems without custom code. Coupled with MCP gateways that enforce HIPAA‑grade security and audit trails, health organizations can maintain data sovereignty while providing real‑time, context‑aware access to researchers. Advanced de‑identification pipelines—ranging from rule‑based NLP to large‑language‑model‑driven redaction—balance privacy with utility, with per‑million‑document costs spanning $2.4 k to $21 k, influencing scalability decisions.

The market response is already visible. Platforms such as Truveta and the Mayo Clinic Platform have aggregated billions of de‑identified records, generating multi‑billion‑dollar revenues and accelerating clinical trial recruitment, target identification, and regulatory submissions. Yet public acceptance remains a hurdle; only about a quarter of patients are comfortable sharing data with commercial tech firms, underscoring the need for transparent governance and a strong social license. Health‑system CEOs that prioritize modular, interoperable AI stacks, robust de‑identification, and proactive stakeholder engagement will capture the highest share of the projected $293 M data‑monetisation market and secure a sustainable competitive advantage.